FDA Inspection 1310500 — Abbisko Therapeutics Co., Ltd.

Abbisko Therapeutics Co., Ltd. — FEI 3020982471

The FDA completed an inspection of Abbisko Therapeutics Co., Ltd. on March 20, 2026 in Pudong New Area. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
March 20, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Pudong New Area (China)

Additional Details

Sponsor, Contract Research Organization

Citations

IDCFRDescription
748221 CFR 312.50General responsibilities of sponsors